drugset / Trial / NCT00003528

Raltitrexed in Treating Children With Refractory Acute Leukemia

NCT00003528

Phase 1 Completed 30 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase I trial to study the effectiveness of raltitrexed in treating children with refractory acute leukemia. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Timeline

Start
1998-09
Primary completion
2002-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltitrexed Small molecule Intravenous